Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subject meets all of the following criteria:~* Scheduled for an outpatient ERCP to diagnose a potential biliary disorder (such as an indeterminate biliary stricture)~* Subject is medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities)~* Age 18 to 100 years~* Willing and able to sign informed consent~Exclusion Criteria:~* Subjects with known allergy or negative reaction to any components of the study drug (list these)~* Subjects on active chemotherapy or radiation treatment~* Pregnant or trying to conceive~* Anything that, in the opinion of the investigator, would place the individual at increased risk or preclude the individual's full compliance with or completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Dimer Application with SFE imaging (Type: EXPERIMENTAL): Subjects having a standard-of-care ERCP will have the dimer sprayed on an area of interest in the bile duct and images taken with the SFE.

Based on this trial design, predict the completion outcome and termination type (if applicable).